| Name | Title | Contact Details |
|---|---|---|
Ashley Felton |
People Business Partner, Associate Director | Profile |
Sarah Larson |
Head of Talent Management and Experience | Profile |
Daniel Peterson |
Associate Marketing Director | Profile |
Matt Larson |
Director of Research & Development | Profile |
Byoungsok Jung |
VP of R&D | Profile |
Chromotrax is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
IMS Group is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Our patented and award-winning Highlight® technology makes it easy to use disinfectants correctly.
Harmony Biosciences, LLC, is a private biopharmaceutical company headquartered in Plymouth Meeting, PA. The company was established in October 2017 with a vision to develop and commercialize novel treatment options for people living with rare diseases. With a focus on the central nervous system, including disorders of sleep and wakefulness, Harmony Biosciences is currently working to advance the understanding of narcolepsy and provide information and resources to people who live with, and healthcare professionals who treat, this chronic, debilitating neurologic disorder.
Calithera is discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Tumor metabolism and tumor immunology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients. Our lead product candidate in tumor metabolism, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. We are currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors. In tumor immunology, our lead preclinical program is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Our ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets.